FR2782524B1 - Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre - Google Patents

Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre

Info

Publication number
FR2782524B1
FR2782524B1 FR9810636A FR9810636A FR2782524B1 FR 2782524 B1 FR2782524 B1 FR 2782524B1 FR 9810636 A FR9810636 A FR 9810636A FR 9810636 A FR9810636 A FR 9810636A FR 2782524 B1 FR2782524 B1 FR 2782524B1
Authority
FR
France
Prior art keywords
activation
implementation
methods
natural killer
killer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9810636A
Other languages
English (en)
Other versions
FR2782524A1 (fr
Inventor
Laurence Zitvogel
Nadine Fernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Original Assignee
Institut Gustave Roussy (IGR)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy (IGR) filed Critical Institut Gustave Roussy (IGR)
Priority to FR9810636A priority Critical patent/FR2782524B1/fr
Priority to US09/260,512 priority patent/US6849452B1/en
Priority to CA002322712A priority patent/CA2322712A1/fr
Priority to JP05552899A priority patent/JP3541140B2/ja
Priority to TW088103226A priority patent/TW585915B/zh
Priority to AU32579/99A priority patent/AU758622B2/en
Priority to EP99937940A priority patent/EP1080184A1/fr
Priority to PCT/FR1999/000482 priority patent/WO1999045102A1/fr
Publication of FR2782524A1 publication Critical patent/FR2782524A1/fr
Application granted granted Critical
Publication of FR2782524B1 publication Critical patent/FR2782524B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR9810636A 1998-03-03 1998-08-21 Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre Expired - Fee Related FR2782524B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR9810636A FR2782524B1 (fr) 1998-08-21 1998-08-21 Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
US09/260,512 US6849452B1 (en) 1998-03-03 1999-03-02 Methods for activating natural killer (NK) cells and means for carrying out said methods
JP05552899A JP3541140B2 (ja) 1998-03-03 1999-03-03 ナチュラルキラー（ｎｋ）細胞の活性化方法及びその実施手段
TW088103226A TW585915B (en) 1998-03-03 1999-03-03 Methods for activating natural killer (NK) cells
CA002322712A CA2322712A1 (fr) 1998-03-03 1999-03-03 Methodes d'activation de cellules tueuses naturelles (nk)
AU32579/99A AU758622B2 (en) 1998-03-03 1999-03-03 Method for activating natural killer (NK) cells
EP99937940A EP1080184A1 (fr) 1998-03-03 1999-03-03 Methodes d'activation de cellules tueuses naturelles (nk)
PCT/FR1999/000482 WO1999045102A1 (fr) 1998-03-03 1999-03-03 Methodes d'activation de cellules tueuses naturelles (nk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9810636A FR2782524B1 (fr) 1998-08-21 1998-08-21 Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre

Publications (2)

Publication Number Publication Date
FR2782524A1 FR2782524A1 (fr) 2000-02-25
FR2782524B1 true FR2782524B1 (fr) 2002-07-19

Family

ID=9529832

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9810636A Expired - Fee Related FR2782524B1 (fr) 1998-03-03 1998-08-21 Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre

Country Status (1)

Country Link
FR (1) FR2782524B1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002156A1 (fr) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Procedes d'utilisation de cellules dendritiques pour activer des lymphocytes t
WO1995034638A1 (fr) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Procedes pour l'activation de lymphocytes t in vivo par des cellules dendritiques a impulsions antigeniques
AU697539B2 (en) * 1995-10-04 1998-10-08 Immunex Corporation Dendritic cell stimulatory factor

Also Published As

Publication number Publication date
FR2782524A1 (fr) 2000-02-25

Similar Documents

Publication Publication Date Title
PL346653A1 (en) Methods, instruments and materials for chondrocyte cell transplantation
NO20001015D0 (no) Cellulosestruktur med forskjellig densitet og fremgangsmõte for fremstilling derav
DE69737948D1 (de) Vorrichtung zur rekonstruktion von sehnen
EP1051624A4 (fr) Series haute densite pour l'analyse des proteomes et procedes et compositions pour ces derniers
FR2739028B1 (fr) Dispositif d'encapsulation de cellules ameliore
EP0961824A4 (fr) Procede d'activation de cellules dendritiques
BR9610852A (pt) Agonista beta3 adrenérgicos seletivos
ZA983540B (en) Method of producing hydrogen using solid electrolyte membrane
EP1109921A4 (fr) Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
PL336693A1 (en) Novel method of obtaining farmacologically active substances
EP0830448A4 (fr) Procede de developpement par clonage selectif en continu de cellules relativement non differenciees
AU6505299A (en) Methods for generating antigen-reactive t cells (in vitro)
NO975557D0 (no) Immortalisering og dismortalisering av celler
IT1298602B1 (it) Modulo solare e procedimento per la sua fabbricazione
EP1109931A4 (fr) PROCEDE D'ETUDE D'INTERACTIONS DE PROTEINES $i(IN VIVO)
DE69606691D1 (de) Silikonhaltige Blockcopolymere
FR2775692B1 (fr) Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
FR2782524B1 (fr) Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
PL337716A1 (en) Method of obtaining thiazafurin and other c-nucleosides
ITMI991318A0 (it) Procedimento per la preparazione di aromatici idrossilati con idrogeno e ossigeno
NO951479D0 (no) Fremgangsmåte og anordning ved oppankret fartöy
NO20012667L (no) Fremgangsmåte for aktivering av vann og anvendelse av aktivert vann av denne type
ID15869A (id) Penerima banyak kanal yang menggunakan analisis melaliu sintetis
DE69523956D1 (de) Vermehrung von knochenmarksstützzellen
EP1051507A4 (fr) Cellules specifiques d'antigenes, procedes de production et utilisations associes

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20060428